Manage your formulary budget
Drug patents …
… from Kazakhstan to Kalamazoo
Proactively manage your pharmacy inventory
Find generic entry opportunities
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Anticipate generic drug launch
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Pharmaceutical compositions containing furan derivatives|
|Abstract:||The invention relates to a pharmaceutical composition in solid unit dosage form adapted for oral administration, comprising a salt formed between ranitidine and a complex of bismuth with a carboxylic acid selected from tartaric acid and citric acid together with an alkaline salt. For example the composition is in tablet form and comprises ranitidine bismuth citrate and sodium carbonate. The composition shows improved disintegration and/or dissolution.|
|Inventor(s):||Smith; Norman R. (London, GB2), Heppenstall; Colin R. (Bishops Stortford, GB2), Douglas; Stephen J. (St. Albans, GB2)|
|Assignee:||Glaxo Group Limited (Middlesex, GB)|
Patent Claim Types:|
see list of patent claims
|Composition; Formulation; Dosage form;|
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|United Kingdom||9019875||Sep 11, 1990|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Austria||122883||<disabled in preview>|
|Austria||405134||<disabled in preview>|
|Austria||A180191||<disabled in preview>|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.